Enrollment Now Complete for PROOF-HD Trial of Oral Pridopidine

Enrollment Now Complete for PROOF-HD Trial of Oral Pridopidine

310873

Enrollment Now Complete for PROOF-HD Trial of Oral Pridopidine

A Phase 3 clinical trial investigating the efficacy and safety of oral pridopidine for those with early stage Huntington’s disease is now underway at more than 50 clinical sites in the U.S., the U.K., Canada, and Europe, according to Prilenia Therapeutics, which is developing the treatment candidate. Prilenia announced that it has completed recruitment for its PROOF-HD (NCT04556656) trial, with more than 480 patients now enrolled — surpassing the initial target, and ahead of schedule. “We…

You must be logged in to read/download the full post.